Compare Adaptive Biotechnologies Corp (ADPT) vs Micron Technology, Inc. (MU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Micron Technology, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $20.12 (market cap $3.33B), while Micron Technology, Inc. trades at $938.8 (market cap $1.06T). The key difference: Micron Technology, Inc. is far larger — about 318.3× Adaptive Biotechnologies Corp's market cap, and Micron Technology, Inc. pays a 0.06% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | MU | |
|---|---|---|
Market Cap | $3.33B | $1.06T |
Sector | Health | Technology |
52-Week High | $22.37 | $1.21K |
52-Week Low | $10.24 | $104.88 |
Enterprise Value | $3.19B | $1.04T |
Dividend Yield | — | 0.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Micron Technology (MU) trades at $938.38, down 3.81% amid a sector-wide chip stock selloff, despite strong fundamentals including a 22.84% net margin and three consecutive quarterly earnings beats. The stock shows a bullish technical trend with support near $933, while analyst consensus remains strongly positive with a $1,540 price target. Recent news highlights AI-driven demand and new supply deals with Ford and GM, though competition and cyclicality pose risks.
Outlook is positive given robust earnings growth and AI memory demand, but investors face volatility from memory market cycles and competitive pressures. The stock offers upside to analyst targets if execution continues, yet macroeconomic and sector rotations could drive near-term swings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →
